Lupus anticoagulant is the main predictor of adverse pregnancy outcomes in aPL-positive patients: Validation of PROMISSE study results

Lupus Science and Medicine

Volumn 3, Issue 1, 2016, Pages

  Yelnik, Cecile M ^a,b   Laskin, Carl A ^c   Porter, T Flint ^d   Branch, D Ware ^d   Buyon, Jill P ^e   Guerra, Marta M ^a   Lockshin, Michael D ^a   Petri, Michelle ^f   Merrill, Joan T ^g   Sammaritano, Lisa R ^a   Kim, Mimi Y ^h   Salmon, Jane E ^a  

^a HOSPITAL FOR SPECIAL SURGERY   (United States)

^b UNIV LILLE   (France)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^e NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

^h ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Antiphospholipid Antibodies; Antiphospholipid Syndrome; Lupus Anticoagulant; Pregnancy; Systemic Lupus Erythematosus

Indexed keywords

ACETYLSALICYLIC ACID; AZATHIOPRINE; CORTICOSTEROID; HEPARIN; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN; LOW MOLECULAR WEIGHT HEPARIN; LUPUS ANTICOAGULANT; PHOSPHOLIPID ANTIBODY;

ADULT; ADVERSE OUTCOME; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; CLINICAL ARTICLE; FEMALE; FETUS DEATH; FIRST TRIMESTER PREGNANCY; HUMAN; LOW DRUG DOSE; MATERNAL HYPERTENSION; MEDICAL HISTORY; MULTICENTER STUDY; NEWBORN DEATH; OBSERVATIONAL STUDY; PLACENTA INSUFFICIENCY; PREDICTION; PREECLAMPSIA; PREGNANCY OUTCOME; PREMATURE LABOR; PREMATURITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; SECOND TRIMESTER PREGNANCY; SMALL FOR DATE INFANT; SYSTEMIC LUPUS ERYTHEMATOSUS; THIRD TRIMESTER PREGNANCY; THROMBOSIS PREVENTION;

EID: 84980686894     PISSN: None     EISSN: 20538790     Source Type: Journal    
DOI: 10.1136/lupus-2015-000131     Document Type: Article

References (12)

1. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006;4:295-306.
2. Abou-Nassar K, Carrier M, Ramsay T, et al. The association between antiphospholipid antibodies and placenta mediated complications: a systematic review and meta-analysis. Thromb Res 2011;128:77-85.
3. De Jesus GR, Agmon-Levin N, Andrade CA, et al. 14th International Congress on Antiphospholipid Antibodies Task Force report on obstetric antiphospholipid syndrome. Autoimmun Rev 2014;13:795-813.
4. Lockshin MD, Kim M, Laskin CA, et al. Prediction of adverse pregnancy outcome by the presence of lupus anticoagulant, but not anticardiolipin antibody, in patients with antiphospholipid antibodies. Arthritis Rheum 2012;64:2311-8.
5. Buyon JP, Kim MY, Guerra MM, et al. Predictors of pregnancy outcomes in patients with lupus: a cohort study. Ann Intern Med 2015;163:153-63.
6. Helgadottir LB, Skjeldestad FE, Jacobsen AF, et al. The association of antiphospholipid antibodies with intrauterine fetal death: a case-control study. Thromb Res 2012;130:32-7.
7. Alijotas-Reig J, Ferrer-Oliveras R, Ruffatti A, et al. The European Registry on Obstetric Antiphospholipid Syndrome (EUROAPS): a survey of 247 consecutive cases. Autoimmun Rev 2015;14:387-95.
8. Ruffatti A, Calligaro A, Hoxha A, et al. Laboratory and clinical features of pregnant women with antiphospholipid syndrome and neonatal outcome. Arthritis Care Res 2010;62:302-7.
9. Ruffatti A, Tonello M, Visentin MS, et al. Risk factors for pregnancy failure in patients with anti-phospholipid syndrome treated with conventional therapies: a multicentre, case-control study. Rheumatol Oxf Engl 2011;50:1684-9.
10. Ruiz-Irastorza G, Crowther M, Branch W, et al. Antiphospholipid syndrome. Lancet 2010;376:1498-509.
11. Mak A, Cheung MW-L, Cheak AA, et al. Combination of heparin and aspirin is superior to aspirin alone in enhancing live births in patients with recurrent pregnancy loss and positive anti-phospholipid antibodies: a meta-analysis of randomized controlled trials and meta-regression. Rheumatol Oxf Engl 2010;49:281-8.
12. Amengual O, Fujita D, Ota E, et al. Primary prophylaxis to prevent obstetric complications in asymptomatic women with antiphospholipid antibodies: a systematic review. Lupus 2015;24:1135-42.